The sale of Theramex, the global specialty pharmaceuticals company focused on women's health, by CVC Capital Partners VI to global investment firms Carlyle and PAI Partners has now completed.
We advised the management team of Theramex on this sale which will enable the business to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion. The investment in Theramex builds on Carlyle’s long-term global focus on healthcare, a sector in which the firm has invested $15 billion to date.
Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018 and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health.
The transaction was led by partner Emma Danks with support from partner Suzy Davis, senior associate Alex Holden and associate Kayla Sinclair in the private equity group.
Additional support was provided by partner Graham Samuel-Gibbon, senior counsel Clare Smith and Pip Moss in the tax & incentives team, and partner Colin McCall and senior associate Sumer Dayal in the IP team.
